Moderna Inc
Stocks making the biggest moves midday: Gilead Sciences, CVS, Electronic Arts and more
A customer walks towards the entrance of a CVS Health Corp. store in downtown Los Angeles, California, U.S., on Friday, Oct. 27, 2017. Christopher Lee | Bloomberg | Getty Images Check out the companies making headlines in midday trading Wednesday. Gilead Sciences — Shares of the biopharma company rose 6.6% after quarterly revenue of $6.26 […]
Read More
Stocks making the biggest moves premarket: CVS, Under Armour, Moderna and more
Check out the companies making headlines before the bell: CVS Health (CVS) – The drugstore operator and pharmacy benefits manager saw its shares rise 3.8% in the premarket after beating top- and bottom-line estimates and raising its full-year earnings forecast. Results were helped by strong sales of over-the-counter Covid-19 tests as well as an upbeat […]
Read More
Moderna’s 2Q earnings beat expectations, but it writes off $500 million in expiring Covid shots
Illustration of a vial of Moderna vaccine for coronavirus treatment. Marcos Del Mazo | Lightrocket | Getty Images Moderna on Wednesday reported second quarter results that beat earnings and revenue expectations driven $4.5 billion in sales from its Covid -19 vaccine, but it’s still the company’s only commercially available product and it took a big […]
Read More
U.S. secures 171 million omicron Covid shots ahead of fall vaccination campaign
A healthcare worker administers a dose of the Pfizer-BioNTech Covid-19 vaccine at a vaccination clinic in the Peabody Institute Library in Peabody, Massachusetts, U.S., on Wednesday, Jan. 26, 2022. Vanessa Leroy | Bloomberg | Getty Images The Health and Human Services Department has secured 171 million doses of new Covid vaccines that target the omicron […]
Read More
Despite concerns, ESG strategies may become a crowded trade for impact investors – so Vanguard is taking a different track
It’s a fund looking to make money from green investing. The inclusive, actively managed Vanguard Baillie Gifford Global Positive Impact Stock Fund (VBPIX) is an environmental, social and governance product that bundles companies with positive, inclusive and sustainable intentions. “It’s really a fund that’s going to be investing in global equities looking to deliver long-term […]
Read More
FDA authorizes Novavax Covid vaccine for adults as the first new shots in U.S. in more than a year
In this photo illustration the Food and Drug Administration (FDA) and Novavax logos are seen behind a medical syringe and vials. Pavlo Gonchar | LightRocket | Getty Images The Food and Drug Administration has authorized Novavax’s two-dose vaccine for adults ages 18 and over, the fourth Covid shot to get emergency approval in the U.S. […]
Read More
Cramer’s lightning round: Gentex is a buy
Chegg Inc: “I don’t know what to make of Chegg. … To me, it seems like the bulls are going to win on this stock.” Moderna Inc: “I think that stock has now come down enough. I would want to own Moderna. I do like Pfizer more.” ONEOK Inc: “Keep it. … I think that’s […]
Read More
FDA panel recommends changing Covid shots to fight omicron this fall
A healthcare worker prepares a syringe with the Moderna COVID-19 vaccine at a pop-up vaccination site operated by SOMOS Community Care during the COVID-19 pandemic in Manhattan in New York City, January 29, 2021. Mike Segar | Reuters The Food and Drug Administration’s panel of independent vaccine experts on Tuesday voted 19 to 2 to […]
Read More
CDC panel recommends Moderna two-dose Covid vaccine for kids ages 6 to 17
The Centers for Disease Control and Prevention is expected to clear Moderna’s two-dose Covid-19 vaccine for kindergartners through high schoolers for public distribution this week after the agency’s panel of independent vaccine experts unanimously voted Thursday to recommend the shots. The committee endorsed Moderna’s vaccine for kids ages 6 to 17 after examining its safety […]
Read More
Moderna to build new vaccine facility in Britain
Jakub Porzycki | NurPhoto | Getty Images U.S. biotech firm Moderna will build a new research and manufacturing center in Britain to develop vaccines against new COVID-19 variants, other respiratory illnesses and help improve readiness for any future pandemics. The facility is expected to start producing shots in 2025 and Britain has made a commitment […]
Read More